READ MOREOver 1,700 employees working in these two factories are expected to be impacted by the decision.
While the company is shutting down the two facilities, plans are afoot to expand the Vizag manufacturing facility, which also came as part of the acquisition.
Pfizer said that it conducted a thorough evaluation of the Irungattukottai and Aurangabad sites and concluded that due to a significant fall in product demand, manufacturing at these sites is not viable.
“As a result, Pfizer is announcing that both the Aurangabad and Irungattukottai sites will immediately cease manufacturing with the intention to exit both sites as soon as possible in 2019. The exact timing of the exit of the sites is to be determined,” said a Pfizer spokesperson. ■